Status:
UNKNOWN
Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
Lead Sponsor:
The Second Affiliated Hospital of Chongqing Medical University
Conditions:
Sustained Virologic Response
Hepatitis B, Chronic
Eligibility:
All Genders
14-70 years
Brief Summary
In the treatment of chronic hepatitis B (CHB), viral suppression is closely related to disease progression, and the lower the viral load, the lower the risk of progression to cirrhosis and hepatocellu...
Detailed Description
In our hospital, about 150 patients are screened for HBV-DNA every day. Therefore, 54 million patients will be tested for HBV-DNA within one year, of which 30% are estimated to be HBV-DNA ≥10 IU. Thes...
Eligibility Criteria
Inclusion
- any patients treated with ETV\\LAM\\ADF\\LDT\\TDF\\TAF.【ADV=adefovir dipivoxil, LAM=lamivudine, and LdT=telbivudine , TAF =Tenofovir alafenamide Fumarate, ETV=Entecavir and TDF=Tenofovir disoproxil fumarate 】
Exclusion
- with a expected life span \<48 weeks
Key Trial Info
Start Date :
December 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT04724785
Start Date
December 1 2020
End Date
December 31 2022
Last Update
August 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The second affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China, 400010